MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS (FORMERLY MCKESSON CORP) lobbying for MCKESSON CORPORATION & AFFILIATES U.S. ONCOLOGY AND RX SAVINGS SOLUTIONS

Filing 1st Quarter - Amendment

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 24, 2025

Expenses

$1,220,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Texas

Official filing document

Lobbyists on this filing 1

BRIAN BRANTON New on this filing

Previously held: Chief of Staff, Congressman Polis; Chief of Staff, Congressman Sestak; Legislative Director, Congressman Wu; Legislative Counsel, Congressman Holt; Legislative Assistant, Congresswoman Mink

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 3

Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 12

HR 4011
Community Paramedicine Act of 2025
S 127
Pharmacy Benefit Manager Transparency Act of 2023
HR 5376
Share the Savings with Seniors Act
S 1339
Pharmacy Benefit Manager Reform Act
HR 2630
Safe Step Act
S 652
Protecting Patients from Deceptive Drug Ads Act
HR 2474
Strengthening Medicare for Patients and Providers Act
HR 3561
PATIENT Act of 2023
HR 4473
Medicare Patient Access to Cancer Treatment Act
HR 2484
Seniors’ Access to Critical Medications Act of 2025
HR 3173
Improving Seniors’ Timely Access to Care Act of 2022
S 3018
Improving Seniors’ Timely Access to Care Act of 2021

Lobbying activity 4

Pharmacy

Equitable Community Access to Pharmacist Services Act; H.R. 4011 Timely Access to Cancer Treatment; Medically integrated physician dispensing regulations; S.127, PBM Transparency Act; Drug price transparency and cost savings opportunities.

Taxation/Internal Revenue Code

Last-in, first-out (LIFO) Inventory Accounting Method; H.R.5376 The Inflation Reduction Act

Health Issues

Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act; H.R.5376 The Inflation Reduction Act.

Medicare/Medicaid

Equitable Community Access to Pharmacist Services Act; Healthcare innovation and oncology research; H.R.3173, S.3018 The Improving Seniors Timely Access to Care Act; Medically integrated physician dispensing regulations; HR 2484 Seniors Access to Critical Medications Act